December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

70.99 -0.33 (-0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
An Overview of Ionis Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For April 30, 2025 ↗
 
Via Benzinga
News headline image
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching ↗
IONIS Pharmaceuticals (NASDAQ:IONS) shows strong technicals with an 8/10 rating and a high-quality setup pattern, making it a breakout candidate for traders. 
Via Chartmill
News headline image
Ionis to hold second quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing. 
Via Benzinga
News headline image
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
News headline image
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
News headline image
Analyst Expectations For Ionis Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts ↗
 
Via Benzinga
News headline image
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to host 2025 virtual Annual Meeting of Stockholders
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge ↗
Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products. 
Via Benzinga
News headline image
Ionis reports first quarter 2025 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to hold first quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' ↗
HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead. 
Via Benzinga
News headline image
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Ionis to host expert panel discussion on sHTG
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts ↗
 
Via Benzinga
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Competitive Analysis In The ATTR-CM Field ↗
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.